RayzeBio, Inc.

If you purchased RayzeBio, Inc. securities and would like to join the action, please click "Join This Action" below.

We would handle the action on a contingent fee basis, whereby you would not be responsible for out of pocket payment of our legal fees or expenses.



December 26, 2023.


New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RayzeBio, Inc. (NASDAQ: RYZB) to Bristol-Myers Squibb Company for $62.50 per share in cash is fair to RayzeBio shareholders.


The investigation concerns whether RayzeBio and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for RayzeBio shareholders; (2) determine whether Bristol-Myers is underpaying for RayzeBio; and (3) disclose all material information necessary for RayzeBio shareholders to adequately assess and value the merger consideration. On behalf of RayzeBio shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.


Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.


Attorney Advertising. Prior results do not guarantee a similar outcome.



Signed pursuant to California Civil Code Section 1633.1, et seq., and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: February 27, 2024